https://www.selleckchem.com/products/sf2312.html
55; 95% CI = 68.46 to 132.63; P less then 0.01) and reduction in CMT (WMD = 0.09; 95% CI = 0.03 to 0.14; P less then 0.01) after switching to aflibercept. Although a large amount of heterogeneity was detected in the CMT results among these studies, the sensitivity analyses showed the reliability and stability of our results. Conclusion and Relevance There were significant improvements in both visual and anatomical outcomes after switching from bevacizumab or ranibizumab to aflibercept, without risk of adverse events. Thus, switching ther
Like
Comment
Share
